The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma
Yıl: 2023 Cilt: 30 Sayı: 3 Sayfa Aralığı: 331 - 336 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2022.12.378 İndeks Tarihi: 06-04-2023
The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma
Öz: Aim: In this single-center, retrospective study, we aimed to evaluate the effect of CD34+ stem cell dose on hematologic recovery and long-term outcomes such as progression-free survival and overall survival after autologous stem cell transplantation (ASCT). Materials and Methods: In this study, 282 patients with MM, who underwent ASCT between January 2014 and October 2021 were evaluated. The patients were divided into 2 groups according to the infused cell dose. Patients who received ≤5x106/kg CD34+ cells were defined as group A. Patients who received >5x106/kg CD34+ cells were group B. The outcome of ASCT including the time of neutrophil/platelet engraftment, febrile neutropenia status, transplant-related mortality (TRM) at 100 days, duration of hospital- ization and survival status were examined in both groups. Results: There were 118 (41.8%) patients in group A and 164 patients (58.2%) in group B. The median neutrophil engraftment was 12 (7-26) days in A group, 11 (6-28) days in B group. The median platelet engraftment was 12 (6-40) and 11 (6-29) days in group B. There were statically significant different in both group for neutrophil and platelet engraftment time (p=.001 and .002, respectively). The median hospitalization time was 16 (10-53) days and 15 (6-83) days in group A and B, respectively. The hospitalization time was statistically significantly different in two groups (p<.012). The mean OS was 53.1±4.2 months in group A and 58.2±3.5 in group B which was not statistically significant difference (p=.841). The mean PFS was 11.8±1.3 months in group A and 19.1±1.4 months in group B which was statistically significant difference in 2 groups (p<0.001). Conclusion: Infusion of >5x106/kg CD34+ stem cells (median dose 9,6 x106/kg) may have a favorable effect on short-term outcomes of transplantation, including short-term neutrophil engraftment, short-term platelet engraftment, and short-term hospitalization. Additionally, progression-free survival may be positively affected by high dose, but upper limit should be defined by new study.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Al Hamed R, Bazarbachi A H, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood cancer journal.2019;9:44.
- 2. Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, et al. Multiple myeloma: Role of autologous transplantation. Cancer treatment reviews.2020;82:101929.
- 3. Mina R and Gay F. The role of autologous stem-cell trans- plantation in multiple myeloma in 2021. Current opinion in oncology.2021;33:642-647.
- 4. Oran B, Malek K, Sanchorawala V, et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone marrow transplantation.2005;35:567-75.
- 5. Pérez-Simón J A, Martín A, Caballero D, et al. Clinical sig- nificance of CD34+ cell dose in long-term engraftment follow- ing autologous peripheral blood stem cell transplantation. Bone marrow transplantation.1999;24:1279-83.
- 6. Giralt S, Stadtmauer E A, Harousseau J L, et al. Interna- tional myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collec- tion and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia.2009;23:1904-12.
- 7. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: con- sensus guidelines and recommendations. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.2014;20:295-308.
- 8. Jillella A P and Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem cells and development.2004;13:598-606.
- 9. Klaus J, Herrmann D, Breitkreutz I, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous pe- ripheral blood stem cell transplantation. European journal of haematology.2007;78:21-8.
- 10. Stiff P J, Micallef I, Nademanee A P, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell trans- plant in patients with non-Hodgkin lymphoma or multiple myeloma. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2011;17:1146-53.
- 11. Weaver C H, Hazelton B, Birch R, et al. An analysis of engraft- ment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the admin- istration of myeloablative chemotherapy. Blood.1995;86:3961-9.
- 12. Benedetti G, Patoia L, Giglietti A, et al. Very large amounts of peripheral blood progenitor cells eliminate severe thrombo- cytopenia after high-dose melphalan in advanced breast cancer patients. Bone marrow transplantation.1999;24:971-9.
- 13. Greipp P R, San Miguel J, Durie B G, et al. International staging system for multiple myeloma. Journal of clinical on- cology : official journal of the American Society of Clinical Oncology.2005;23:3412-20.
- 14. Durie B G, Harousseau J L, Miguel J S, et al. Inter- national uniform response criteria for multiple myeloma. Leukemia.2006;20:1467-73.
- 15. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood.1995;85:588-96.
- 16. Çelikzencir H. Investigation of the relationship between CD34 + and CD34 + CD133 + characterized stem cell range collected from allogenic and otologic transmissions with mobilization and clinical results. Master Thesis, Erciyes University, 2019.
- 17. Aladağ Karakulak E, Demiroğlu H, Büyükaşik Y, et al. CD34+ hematopoietic progenitor cell dose as a predictor of engraft- ment and survival in multiple myeloma patients undergoing au- tologous stem cell transplantation. Turkish journal of medical sciences.2020;50:1851-1856.
- 18. Sarıcı A, Erkurt M A, Bahçecioğlu Ö F, et al. Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in mul- tiple myeloma patients. Transfusion and apheresis science : offi- cial journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.2021;60:103159.
- 19. Zannetti B A, Saraceni F, Cellini C, et al. Low-Dose Cyclophos- phamide versus Intermediate-High-Dose Cyclophosphamide ver- sus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. Transplantation and cellular therapy.2021;27:244.e1-244.e8.
- 20. Lebel E, Lajkosz K, Masih-Khan E, et al. Supermobilizers with High CD34 + Cell Collection for Autologous Trans- plant and Impact on Survival Outcomes in Multiple Myeloma. Blood.2021;138:1837.
| APA | Uysal A, ERKURT M, KUKU I, Kaya E, BERBER I, SARICI A, Biçim S, kaya a, Hidayet E, DAĞOĞLU HARK B, ARSLAN S (2023). The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. , 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| Chicago | Uysal Ayse,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,SARICI AHMET,Biçim Soykan,kaya ahmet,Hidayet Emine,DAĞOĞLU HARK Betül,ARSLAN SÜLEYMAN The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. (2023): 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| MLA | Uysal Ayse,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,SARICI AHMET,Biçim Soykan,kaya ahmet,Hidayet Emine,DAĞOĞLU HARK Betül,ARSLAN SÜLEYMAN The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. , 2023, ss.331 - 336. 10.5455/annalsmedres.2022.12.378 |
| AMA | Uysal A,ERKURT M,KUKU I,Kaya E,BERBER I,SARICI A,Biçim S,kaya a,Hidayet E,DAĞOĞLU HARK B,ARSLAN S The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. . 2023; 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| Vancouver | Uysal A,ERKURT M,KUKU I,Kaya E,BERBER I,SARICI A,Biçim S,kaya a,Hidayet E,DAĞOĞLU HARK B,ARSLAN S The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. . 2023; 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| IEEE | Uysal A,ERKURT M,KUKU I,Kaya E,BERBER I,SARICI A,Biçim S,kaya a,Hidayet E,DAĞOĞLU HARK B,ARSLAN S "The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma." , ss.331 - 336, 2023. 10.5455/annalsmedres.2022.12.378 |
| ISNAD | Uysal, Ayse vd. "The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma". (2023), 331-336. https://doi.org/10.5455/annalsmedres.2022.12.378 |
| APA | Uysal A, ERKURT M, KUKU I, Kaya E, BERBER I, SARICI A, Biçim S, kaya a, Hidayet E, DAĞOĞLU HARK B, ARSLAN S (2023). The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. Annals of Medical Research, 30(3), 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| Chicago | Uysal Ayse,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,SARICI AHMET,Biçim Soykan,kaya ahmet,Hidayet Emine,DAĞOĞLU HARK Betül,ARSLAN SÜLEYMAN The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. Annals of Medical Research 30, no.3 (2023): 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| MLA | Uysal Ayse,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,SARICI AHMET,Biçim Soykan,kaya ahmet,Hidayet Emine,DAĞOĞLU HARK Betül,ARSLAN SÜLEYMAN The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. Annals of Medical Research, vol.30, no.3, 2023, ss.331 - 336. 10.5455/annalsmedres.2022.12.378 |
| AMA | Uysal A,ERKURT M,KUKU I,Kaya E,BERBER I,SARICI A,Biçim S,kaya a,Hidayet E,DAĞOĞLU HARK B,ARSLAN S The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. Annals of Medical Research. 2023; 30(3): 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| Vancouver | Uysal A,ERKURT M,KUKU I,Kaya E,BERBER I,SARICI A,Biçim S,kaya a,Hidayet E,DAĞOĞLU HARK B,ARSLAN S The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. Annals of Medical Research. 2023; 30(3): 331 - 336. 10.5455/annalsmedres.2022.12.378 |
| IEEE | Uysal A,ERKURT M,KUKU I,Kaya E,BERBER I,SARICI A,Biçim S,kaya a,Hidayet E,DAĞOĞLU HARK B,ARSLAN S "The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma." Annals of Medical Research, 30, ss.331 - 336, 2023. 10.5455/annalsmedres.2022.12.378 |
| ISNAD | Uysal, Ayse vd. "The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma". Annals of Medical Research 30/3 (2023), 331-336. https://doi.org/10.5455/annalsmedres.2022.12.378 |
